Aggarwal, Charu http://orcid.org/0000-0002-3181-9460
Rolfo, Christian D. http://orcid.org/0000-0002-5109-0267
Oxnard, Geoffrey R.
Gray, Jhanelle E.
Sholl, Lynette M.
Gandara, David R.
Article History
Accepted: 24 July 2020
First Online: 11 September 2020
Competing interests
: C.A. has received consultancy fees or honoraria from AstraZeneca, BMS, Celgene, Lilly, Merck, and Roche-Genentech and institutional research funding from Macrogenics, Merck, Novartis, and Xencor. C.D.R. has received honoraria from AstraZeneca and MSD, consultancy fees from Archer, EMD, Inivata, Mylan, and Serono and has acted as an adviser (non-compensated) of Oncompass. G.R.O. became a full-time employee of Foundation Medicine after submission of this manuscript and has received consultancy fees or honoraria from Abbvie, AstraZeneca, Blueprint, Dropworks, Foundation Medicine, GRAIL, Guardant Health, Illumina, Inivata, Janssen, Loxo Oncology, Sysmex, and Takeda and institutional research funding from GRAIL. J.E.G. has received consultancy fees from AstraZeneca, BMS, EMD Serono/Merck KGaA, Inivata, Merck, and Novartis and institutional research funding from Array, AstraZeneca, BMS, Boehringer–Ingelheim, Merck and Roche-Genentech. L.M.S. has received consultancy fees or honoraria from AstraZeneca, EMD Serono, Foghorn Therapeutics, and Loxo Oncology and institutional research funding from Roche Genentech. D.R.G. has received consultancy fees from AstraZeneca, Celgene, FujiFilm, Guardant Health, Inivata, IO Biotech, Lilly, Merck, Oncocyte, Roche-Genentech, and Samsung Bioepis and institutional research funding from Amgen, Astex, Merck, and Roche-Genentech.